Sei Investments Co. grew its holdings in SAGE Therapeutics Inc (NASDAQ:SAGE) by 225,380.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,274 shares of the biopharmaceutical company’s stock after buying an additional 11,269 shares during the quarter. Sei Investments Co.’s holdings in SAGE Therapeutics were worth $1,764,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Allianz Asset Management GmbH increased its position in shares of SAGE Therapeutics by 962.4% during the first quarter. Allianz Asset Management GmbH now owns 44,474 shares of the biopharmaceutical company’s stock worth $7,163,000 after purchasing an additional 40,288 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of SAGE Therapeutics by 58.9% during the second quarter. Wells Fargo & Company MN now owns 279,456 shares of the biopharmaceutical company’s stock worth $43,743,000 after purchasing an additional 103,562 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of SAGE Therapeutics by 93.6% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 4,774 shares of the biopharmaceutical company’s stock worth $747,000 after purchasing an additional 2,308 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its position in shares of SAGE Therapeutics by 186.2% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 89,256 shares of the biopharmaceutical company’s stock worth $13,971,000 after purchasing an additional 58,069 shares in the last quarter. Finally, UBS Group AG increased its position in shares of SAGE Therapeutics by 242.6% during the first quarter. UBS Group AG now owns 23,493 shares of the biopharmaceutical company’s stock worth $3,785,000 after purchasing an additional 16,636 shares in the last quarter.

Shares of NASDAQ:SAGE opened at $163.49 on Friday. SAGE Therapeutics Inc has a 52-week low of $59.57 and a 52-week high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.84) by $1.48. The company had revenue of $90.00 million during the quarter. equities analysts anticipate that SAGE Therapeutics Inc will post -7.37 EPS for the current fiscal year.

Several analysts recently commented on SAGE shares. BidaskClub upgraded SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 30th. Stifel Nicolaus boosted their price target on SAGE Therapeutics from $198.00 to $239.00 and gave the stock a “buy” rating in a research report on Tuesday, August 7th. LADENBURG THALM/SH SH started coverage on SAGE Therapeutics in a research report on Wednesday, June 6th. They set a “buy” rating and a $230.00 price target for the company. Morgan Stanley boosted their price target on SAGE Therapeutics from $225.00 to $228.00 and gave the stock an “overweight” rating in a research report on Friday, July 13th. Finally, Canaccord Genuity set a $220.00 price target on SAGE Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, fifteen have given a buy rating and one has given a strong buy rating to the company. SAGE Therapeutics presently has an average rating of “Buy” and a consensus target price of $199.19.

SAGE Therapeutics Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Read More: Calculate Your Return on Investment (ROI)

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.